FTC Challenges Amgen's Patent Acquisition from Roche as Anticompetitive

The FTC urged the Fourth Circuit to reject Amgen's acquisition of Roche's patent applications to extend Enbrel exclusivity, arguing the deal threatens to upend long-settled antitrust framework. This challenges the assumption that patent enforcement automatically shields such acquisitions. A critical signal for IP strategists and litigators on the intersection of patent law and antitrust.